Immunovia AB (FRA:1YR)
€ 0.0338 0.0013 (4%) Market Cap: 8.99 Mil Enterprise Value: 6.59 Mil PE Ratio: 0 PB Ratio: 2.83 GF Score: 42/100

Q4 2019 Immunovia AB (publ) Earnings Call Transcript

Feb 14, 2020 / 07:30AM GMT
Operator

Hello and welcome to the Immunovia Full Year 2019 Results Call. My name is Courtney, and I will be your coordinator for today's event. Please note that this conference is being recorded. (Operator Instructions)

And I will now hand you over to your host, Mats Grahn, to begin today's conference. Thank you.

Mats Grahn;publ;CEO
Immunovia AB

()-

Thank you and it's a true pleasure to welcome you to this telecom conference talking about Immunovia's results in 2019.

2019 was a very successful year. I am extremely proud of the results achieved in the studies done in the early detection of pancreatic cancer for our product, IMMray PanCan-d, both the optimization where we showed fantastic results in all relevant risk groups and the Commercial Test Model study where we stress tested the commercial version and made it ready for the final stretch towards sales starts in Q3 and now 2020.

Great. Thanks to our team, R&D, production, quality. Everybody worked really hard to achieve these results. And at the same

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot